Perspectives on Breast Cancer Management: Tailoring Treatment to the Individual Patient.
作者信息
Thomssen Christoph
机构信息
Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle/Saale, Germany.
出版信息
Breast Care (Basel). 2008;3(s1):21-23. doi: 10.1159/000119749. Epub 2008 Apr 25.
Abstract
摘要
相似文献
1
Perspectives on Breast Cancer Management: Tailoring Treatment to the Individual Patient.乳腺癌管理的观点：为个体患者量身定制治疗方案。
Breast Care (Basel). 2008;3(s1):21-23. doi: 10.1159/000119749. Epub 2008 Apr 25.
2
How does a new patient education programme for renal recipients become situated and adapted when implemented in the daily teaching practice in a university hospital? An ethnographic observation study.新的肾脏受赠者教育计划如何在大学附属医院的日常教学实践中得到实施和调整？一项民族志观察研究。
BMJ Open. 2018 Nov 25;8(11):e023005. doi: 10.1136/bmjopen-2018-023005.
3
Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.连续的磁共振成像扫描有助于评估对新辅助化疗的早期反应，并为乳腺癌治疗制定个性化方案。
Eur J Surg Oncol. 2016 Jul;42(7):965-72. doi: 10.1016/j.ejso.2016.03.019. Epub 2016 Apr 20.
4
Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.当前乳腺导管原位癌的治疗趋势和对更好预测工具的需求。
Cancer Treat Rev. 2017 Apr;55:163-172. doi: 10.1016/j.ctrv.2017.03.009. Epub 2017 Mar 31.
5
[Evaluation of the immune infiltrate in breast cancer].[乳腺癌免疫浸润的评估]
Bull Cancer. 2017 Jan;104(1):52-68. doi: 10.1016/j.bulcan.2016.11.010. Epub 2016 Dec 13.
6
Breast cancer treatment and work disability: patient perspectives.乳腺癌治疗与工作失能：患者视角。
Breast. 2011 Dec;20(6):534-8. doi: 10.1016/j.breast.2011.06.002. Epub 2011 Jul 1.
7
Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives.乳腺癌辅助放疗的最佳时机：全面综述与展望
Crit Rev Oncol Hematol. 2009 Aug;71(2):102-16. doi: 10.1016/j.critrevonc.2008.09.002. Epub 2008 Oct 14.
8
Tailoring PTV expansion to improve the dosimetry of post modified radical mastectomy intensity-modulated radiotherapy for left-sided breast cancer patients by using 4D CT combined with cone beam CT.利用 4DCT 结合锥形束 CT 对左侧乳腺癌改良根治术后调强放疗的 PTV 进行个体化扩边，改善剂量学分布。
J Appl Clin Med Phys. 2021 May;22(5):139-146. doi: 10.1002/acm2.13244. Epub 2021 May 2.
9
Tailoring genetic/genomic services and information to the individual.
Nurs Stand. 2013;28(10):37-43. doi: 10.7748/ns2013.11.28.10.37.e7844.
10
Tailoring interventions for health behavior change in breast cancer screening.为乳腺癌筛查中的健康行为改变量身定制干预措施。
Cancer Pract. 1997 Sep-Oct;5(5):283-8.
引用本文的文献
1
Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.转移性乳腺癌患者外周血循环肿瘤细胞的多标志物分析：个性化医疗的一大进步。
Breast Care (Basel). 2012 Feb;7(1):7-12. doi: 10.1159/000336548. Epub 2012 Feb 21.
本文引用的文献
1
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.美国临床肿瘤学会2007年乳腺癌肿瘤标志物应用建议更新版。
J Clin Oncol. 2007 Nov 20;25(33):5287-312. doi: 10.1200/JCO.2007.14.2364. Epub 2007 Oct 22.
2
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.进展与前景：2007年早期乳腺癌主要治疗国际专家共识要点
Ann Oncol. 2007 Jul;18(7):1133-44. doi: 10.1093/annonc/mdm271.
3
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.他莫昔芬生物转化的药物遗传学与疗效及潮热的临床结局相关。
J Clin Oncol. 2005 Dec 20;23(36):9312-8. doi: 10.1200/JCO.2005.03.3266.
4
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.预测淋巴结阴性原发性乳腺癌远处转移的基因表达谱。
Lancet. 2005;365(9460):671-9. doi: 10.1016/S0140-6736(05)17947-1.
5
Outcome signature genes in breast cancer: is there a unique set?乳腺癌的预后特征基因：是否存在一组独特的基因？
Bioinformatics. 2005 Jan 15;21(2):171-8. doi: 10.1093/bioinformatics/bth469. Epub 2004 Aug 12.
6
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.他莫昔芬与选择性5-羟色胺再摄取抑制剂帕罗西汀合用时他莫昔芬活性代谢产物的血浆浓度
J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. doi: 10.1093/jnci/djg108.
7
A gene-expression signature as a predictor of survival in breast cancer.一种作为乳腺癌生存预测指标的基因表达特征。
N Engl J Med. 2002 Dec 19;347(25):1999-2009. doi: 10.1056/NEJMoa021967.
8
Gene expression profiling predicts clinical outcome of breast cancer.基因表达谱分析可预测乳腺癌的临床预后。
Nature. 2002 Jan 31;415(6871):530-6. doi: 10.1038/415530a.
9
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.美国国立卫生研究院共识发展会议声明：乳腺癌辅助治疗，2000年11月1日至3日
J Natl Cancer Inst. 2001 Jul 4;93(13):979-89. doi: 10.1093/jnci/93.13.979.
10
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?血管内皮生长因子（VEGF）能否预测接受放疗的淋巴结阴性乳腺癌的局部复发和生存率？
Br J Cancer. 1999 Oct;81(4):727-32. doi: 10.1038/sj.bjc.6690755.
Zotero 插件